AN2 Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s core technology approach is based on the use of boron chemistry for its drug research and development initiatives. The Company’s lead product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. The Company plans to conduct a Phase 2/3 pivotal clinical trial in treatment-refractory Mycobacterium avium complex lung disease, the most common type of NTM lung disease.